This article is more than 5 years old. Information may no longer be current.

Mavrilimumab improved patient-reported outcomes from patients with RA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patient-reported outcomes that reflected pain, health-related quality of life, physical function and fatigue improved after 12 to 24 weeks of treatment of rheumatoid arthritis with mavrilimumab, according to a recently published phase 2b study.

Researchers studied data from 326 patients with rheumatoid arthritis (RA) treated with 150mg, 100mg or 30mg mavrilimumab (AstraZeneca), a granulocyte-macrophage colony-stimulating factor, or placebo every other week and concomitant methotrexate for 24 weeks. Patients were a mean age of 51.8 years and 86.5% were women with a mean Disease Activity Score in 28 joints and C-reactive protein (DAS28-CRP) of 5.8.

At week 12 and 24, patients in all of the mavrilimumab treatment groups showed improvements in pain, Short-Form-36 (SF-36) Physical and Mental component summaries, Health Assessment Questionnaire (HAQ) scores and the Functional Assessment of Chronic Illness Therapy-Fatigue scores. The primary endpoints of improvement in DAS28-CRP and an American College of Rheumatology (ACR) response of 20% (ACR20) or better were achieved at all doses in the treatment group. Over 50% of patients who received 150mg mavrilimumab achieved a clinically meaningful response and improvements were seen in all patient-reported outcomes except the SF-36 mental component score compared to placebo at week 12 and 24. A response was sustained at week 24 from week 12 in 67% of patients who received 150 mg, in 72.2% of patients who received 100 mg and in 72.2% of patients who received 30 mg. At week 24, HAQ responses were maintained in 78.8% of patients who received 150 mg, in 84% of patients who received 100 mg and in 75% of patients who received 30 mg. – by Shirley Pulawski

Reference:

Kremer JM, et al. Paper #FRI0167. Presented at: European League Against Rheumatism Annual European Congress of Rheumatology. June 10-13, 2015; Rome.

Disclosure: Kremer reports he is a shareholder of Corrona, has obtained grant or research support from AbbVie, Amgen, Genentech, Lilly and Pfizer and is a consultant for AbbVie, Amgen, Genentech, Lilly, Pfizer and . Please see the full study for a list of all other authors’ relevant financial disclosures.